Clinical Trial Update: A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of RO5545965 in schizophrenia patients taking risperidone has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• RISPERIDONE (RISPERIDONE)
• RO5545965 (RO5545965)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED